Randomized multicenter phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma (definitive results of the TEMAVIR ANOCEF study)
B. Chauffert
Randomized multicenter phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma (definitive results of the TEMAVIR ANOCEF study)
B. Chauffert